<DOC>
	<DOCNO>NCT01556152</DOCNO>
	<brief_summary>Diabetic peripheral neuropathy ( DPN ) represent diffuse symmetric length-dependent injury peripheral nerve major implication quality life ( QOL ) , morbidity , cost public health perspective . Painful diabetic neuropathy affect 16 % patient diabetes . Pharmacological agent use management painful DPN mainly include tricyclic antidepressant , selective serotonin norepinephrine reuptake inhibitor , opioids , anti epileptic drug . However , two drug ( duloxetine pregabalin ) formally approve EMEA US FDA treatment painful DPN . Generally , available treatment option give total relief , effective patient , one-third patient may achieve 50 % pain relief . Hence new therapy require treatment DPN . This randomized , double-blind , placebo-controlled , parallel group study . The study include patient type 1 type 2 diabetes mellitus history pain attribute DPN least 6 month great 5 year . Patients recruit provide write informed consent .</brief_summary>
	<brief_title>A Clinical Trial Study Effects GRC 17536 Patients With Painful Diabetic Neuropathy ( Painful Extremities Due Peripheral Nerve Damage Diabetic Patients )</brief_title>
	<detailed_description />
	<mesh_term>Pain</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>1 . Patients willing provide voluntary write informed consent 2 . Male female ( woman non childbearing potential ) patient ≥18 yrs ≤ 75 yr 3 . Patients diabetes mellitus painful peripheral neuropathy least 6 month 4 . A baseline 24hour average daily pain intensity score ≥5 5 . Women must non childbearing potential , define post menopausal surgically sterile . 1 . Other chronic pain condition associate DPN , may confound assessment neuropathic pain 2 . Other cause neuropathy low extremity pain 3 . Complex regional pain syndrome trigeminal neuralgia 4 . Lower extremity amputation toe 5 . Participation another study investigational compound within previous 90 day prior study medication administration , concurrent participation another clinical study 6 . Major depression . 7 . Presence history cancer within past 5 year exception adequately treat localized basal cell skin cancer situ uterine cervical cancer . 8 . Patients clinically significant uncontrolled hepatic , gastrointestinal , cardiovascular , respiratory , neurological ( neuropathy ) , psychiatric , hematological , renal , dermatological disease , medical condition accord Investigator 's medical judgment : Could interfere accurate assessment safety efficacy , , Could potentially affect patient 's safety study outcome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>